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willing to use alternative therapy such as acupuncture (49%
versus 43%, p < 0.001) and more likely to visit an alternative
provider (32% versus 24%, p < 0.001). They are also more likely
to visit a traditional provider (96% versus 92%, p < 0.001) and
do so with greater frequency (visits 7.2 versus 5.6, p < 0.001)
than the general patient population. CONCLUSION: Clinical
trial participants are unique individuals who differ from those in
the general patient population. Therefore, the treatment experi-
ences of clinical trial participants may not always be predictive
of the treatment experiences of the general patient population.
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OBJECTIVES: The purpose of this study was to assess the
overall experience of members enrolled in Consumer Choice
Pharmacy (CCP). CCP is an innovative three-level prescription
beneﬁt plan based on consumer-driven models (Level 1: Phar-
macy account; Level 2: Employee Responsibility; Level 3: 
Traditional Coinsurance). The goal of this program is to assist
members in making more informed personal pharmacy deci-
sions, while contributing to the plan sponsors cost-containment
efforts. METHODS: In April 2005, a survey was mailed to all
member households of an employer group enrolled in CCP to
assess knowledge, perception, satisfaction, and overall experi-
ence with the plan. Response frequencies and means were cal-
culated. Statistical differences in responses based on member
characteristics and pharmacy utilization were also evaluated.
RESULTS: A total of 925 surveys were mailed. Of these, 100
(11%) were returned. Respondents and non-respondents had
similar demographic characteristics, but were different in terms
of pharmacy utilization and spending, with respondents having
both higher utilization and spending. Respondents indicated the
potential to save money was the most inﬂuential factor in their
decision to enroll in the plan. A large proportion of respondents
had a good (30%), very good (29%), or excellent (10%) under-
standing of CCP. Seventy-eight percent indicated that CCP met
or exceeded their expectations. Most respondents indicated their
overall experience was good (38%), very good (13%), or excel-
lent (24%) and were satisﬁed (52%) or very satisﬁed (27%) with
the plan. Respondents with greater than three claims per month
were less satisﬁed (p = 0.004) than those with three or fewer
claims per month. Fifty-three percent would recommend the plan
to others. There were no signiﬁcant differences in overall
responses based on whether or not respondents had money
remaining in their pharmacy accounts. CONCLUSIONS: Survey
results show that respondents generally have a clear under-
standing of CCP and are satisﬁed with the program.
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OBJECTIVES: CDH beneﬁt plans use ﬁnancial incentives for
plan participants to reduce utilization of health services and are
attractive to low utilizers. This study assesses the impact of CDH
design on subsequent utilization by controlling for adverse selec-
tion with a control group. METHODS: Continuously eligible
plan participants of a pharmacy-only CDH plan were analyzed
as a study group identiﬁed through Caremark 2003–2004 phar-
macy claims and eligibility data. A control group matched to the
CDH group was drawn from the non-CDH plan participants
within the same plan sponsor, using stratiﬁed random sampling
within 8 groups based on age, health-risk index, prescription
count and gross costs. Pharmacy utilization patterns were
studied pre-to-post and compared to control. Wilcoxon rank
sums test was used to assess signiﬁcance of differences between
groups and over time, using a p-value of 0.05 for signiﬁcance.
RESULTS: The control (N = 2403) matched the CDH group (N
= 2403) in age (29.8 vs. 29.5), HRI score (4.5 vs. 3.9), and pre-
scriptions (5.0 vs. 4.6). No baseline differences were identiﬁed
(p-values from 0.1751 to 0.4564). Utilization increased between
2003 and 2004 for the control but not for the CDH group. The
CDH group increased prescriptions from 4.61 to 4.90, days’
supply from 101.89 to 111.60 and gross costs from $171.59 to
$190.55, (p = 0.7651 to 0.3501), while the control increased 
prescriptions from 5.03 to 5.99, days’ supply from 113.89 to
142.24, and gross costs from $187.56 to $253.44, (p < 0.0001).
Mail utilization increased for both but substantially more for
CDH (57% increase vs. 19%, p < 0.0001). Generic utilization
and formulary compliance did not differ. Medical costs will be
presented. CONCLUSION: The CDH beneﬁt plan limited an
increase in drug utilization as compared to the traditional plan.
Also, mail utilization increased with CDH.
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OBJECTIVES: To determine the out-of-pocket prices of outpa-
tient prescription drugs using methods that account for the mul-
timodality of their distributions. METHODS: Using data from
the 1992—2002 Medicare Current Beneﬁciary Survey and the
1996—2003 Medical Expenditure Panel Survey, we demonstrate
the multimodality of prices for 175 of the most commonly pre-
scribed medications in the United States. Through the applica-
tion of Gaussian and gamma mixture models, we estimate the
cash price and covered price paid by consumer for each of these
medications, and estimate the percentage of consumers paying
each price. RESULTS: The results suggest that simple averages
of out-of-pocket prices are not applicable for economic evalua-
tions and policy studies in pharmaceutical economics, except in
the case of multisource medications. Without the integration of
price disparities, analyses of single source medications may lead
to erroneous policy conclusion. CONCLUSIONS: Price dispari-
ties may have been the motivation for recent coverage expansion
endevours, such as Medicare Part D. Our results demonstrate 
the prevalence and extent of these price disparities, which 
appear particularly grave in the price distributions of branded
medications.
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